CJC-1295 and ipamorelin belong to a broader class of growth hormone-releasing compounds through related, yet distinct mechanisms. Each peptide discussed below has its own body of research. However, no published human studies have tested CJC-1295 and ipamorelin directly in combination with GHRP-2, GHRP-6, BPC-157, retatrutide, or AOD-9604. This means any comparison here is based on assessing the individual evidence base of each compound, rather than confirmed combination data.
CJC-1295 and Ipamorelin vs. GHRP-2 and GHRP-6
Ipamorelin, GHRP-2, and GHRP-6 all belong to the same broad family of ghrelin receptor agonists, also referred to as growth hormone-releasing peptides. Ipamorelin, however, was specifically developed to be more selective than its predecessors. This difference is well-documented in the foundational research literature. In ipamorelin's original pharmacological characterization, researchers directly compared it to GHRP-6 and GHRP-2 in animal testing and early human-like trials. All three stimulated growth hormone release with roughly comparable potency. GHRP-6 and GHRP-2, however, significantly increased cortisol and ACTH, the stress hormone pathway. Ipamorelin, conversely, did not induce a significant increase in either, even at doses over 200 times higher than needed for its growth hormone-releasing effect [1].
This selectivity is the primary scientific reason why ipamorelin is generally described in research literature as more sophisticated than the older compounds GHRP-2 and GHRP-6. Triggering a lesser stress hormone response, alongside the intended growth hormone release, is generally considered pharmacologically advantageous.
CJC-1295 works differently. Being a GHRH analog, rather than a ghrelin receptor agonist, it functions via a completely separate receptor pathway than any of those three GHRP-type compounds. This is the scientific basis for combining a GHRH analog with a ghrelin receptor agonist in the first place – whether that ghrelin receptor partner is ipamorelin, GHRP-2, or GHRP-6. However, no published study has directly compared outcomes between „CJC-1295 plus ipamorelin” versus „CJC-1295 plus GHRP-6." Any claims that one combination outperforms the other therefore remain untested.
CJC-1295 with BPC-157
CJC-1295 and BPC-157 are often discussed together in contexts focused on regeneration. However, as established in a prior article in this series on joint and injury regeneration, they represent fundamentally different categories of peptides. No published human studies have tested them in combination. CJC-1295 functions by increasing systemic growth hormone and IGF-1 levels [2]. This is a hormonal mechanism with reasonably documented effects on these specific hormonal measurements, but without direct outcome data on tissue healing. BPC-157, on the other hand, has been evaluated in preclinical studies for direct effects on tendon and muscle repair. There is also one small human case series examining knee injections directly into the joint, though a formal review described this case series as having significant methodological flaws and a lack of proper controls [3].
Since these two compounds have been studied through entirely separate research pathways and have never been tested together in a controlled human trial, any specific „CJC-1295 plus BPC-157" protocol or claimed synergistic benefit reflects informal practice, not validated science.
CJC-1295 with retatrutide
Retatrutide is a fundamentally different type of compound than CJC-1295. It is important to clearly state this distinction before considering any combination. Retatrutide is a triple hormone receptor agonist that acts on GLP-1, GIP, and glucagon receptors. It is currently in Phase 3 clinical trials for obesity, being developed by Eli Lilly. It has demonstrated significant weight loss results in published Phase 2 studies. One peer-reviewed study reported weight reductions of up to 24.2% of body weight after 48 weeks in certain dosage groups [4]. According to the latest publicly available information, retatrutide remains an investigational drug. It has not received approval from the FDA, EMA, or any other major drug regulatory authority. It is not legally available as a prescription drug outside of clinical trial settings.
CJC-1295, on the other hand, works through a completely separate growth hormone-releasing hormone pathway, rather than the incretin and glucagon pathways that retatrutide targets. No published studies have tested the two compounds when administered together. Any online discussion of a „CJC-1295 and retatrutide stack” for fat burning reflects a speculative combination of two mechanistically unrelated, individually researched compounds. It is not a studied protocol. And considering that retatrutide itself is not yet an approved drug, this combination carries additional layers of uncertainty beyond those surrounding CJC-1295 alone.
AOD 9604 vs. CJC-1295
AOD-9604 and CJC-1295 both originate from fragments of the growth hormone system. However, they were designed with different goals and have significantly different clinical trial histories that are worth understanding clearly. AOD-9604 is a fragment of human growth hormone, specifically amino acids 176–191. It was developed specifically to isolate the fat-metabolizing properties of growth hormone while minimizing effects on growth and blood sugar. It has undergone an extremely extensive clinical development program for a peptide in this general category, including multiple Phase 2 trials in obese adult humans [5].
An early Phase 2b study did show a statistically significant weight loss compared to placebo at a low, 1-milligram daily oral dose [5]. However, a larger, pivotal trial did not replicate the statistically significant weight loss effect. The formal pharmaceutical development program for the compound was reportedly discontinued following this outcome. This is a significantly more extensive and mixed human clinical trial history than exists for CJC-1295. CJC-1295's own most significant human outcomes trial, in HIV-associated visceral obesity, was not completed at all [6].
Mechanistically, AOD-9604 was designed to act more selectively on fat metabolism, with reduced influence on general growth hormone-driven processes. CJC-1295 raises growth hormone and IGF-1 more broadly throughout the growth hormone axis. This means these two compounds are not interchangeable, despite both stemming from growth hormone-related biology. No published studies have tested AOD-9604 and CJC-1295 in combination. Given AOD-9604's own mixed history of efficacy in dedicated human obesity studies, it would not be accurate to characterize either compound as a clearly superior choice for fat burning based on current evidence.
Limitations of current evidence
The same fundamental limitation applies to all comparisons in this article. Each individual compound has its own separate research history. Some are reasonably significant—six human clinical trials for AOD-9604, cortisol selectivity data for ipamorelin. Others are quite limited—an unfinished obesity study for CJC-1295. Still others are entirely separate and unrelated—the incretin pathway mechanism of semaglutide and an active Phase 3 program.
However, no published studies have directly tested any of these compounds in conjunction with CJC-1295 and ipamorelin as a combined protocol. Comparative claims about which combination „works better” for any specific goal are not supported by direct comparative study evidence and should be considered unsubstantiated.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, therapeutic recommendation, or a comparative product recommendation. CJC-1295, ipamorelin, GHRP-2, GHRP-6, BPC-157, AOD-9604, and retatrutide are research compounds or, in the case of retatrutide, still under investigation. None of the growth hormone peptides discussed herein are approved by the FDA or the European Medicines Agency for general human use. No published human studies have tested CJC-1295 and ipamorelin combined with any of the other compounds discussed in this article.
References
[1] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[2] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[3] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
[4] Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity—A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
Wittert, G. A., Hunter, C. E., Zsombor-Murray, E., et al. (2005). AOD9604, an orally active peptide for the treatment of obesity: Results of a phase 2b study. Diabetes, 54(Suppl. 1), A101.
[6] National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 91971820, CJC-1295 [Clinical trial data: NCT00267527 and EudraCT 2005-003797-25]. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/91971820